I am very happy to announce that Dr. John Haley has joined the faculty of Stony Brook Medicine as an Associate Professor, as a result of joint recruitment efforts by the Department of Pathology and the Cancer Center. Dr. Haley has been recruited to lead his research program in the Department of Pathology and also, to serve as the Director of Developmental Therapeutics in the Cancer Center.
To briefly review his background, Dr. Haley earned a Ph.D. in Molecular Endocrinology from the Howard Florey Institute for Experimental Physiology and the University of Melbourne and completed postdoctoral research fellowships at the Howard Florey Institute in Melbourne and at the Imperial Cancer Research Fund and the Ludwig Institute for Cancer Research in London. He returned to the U.S. to join Oncogene Science Inc. as Program Manager for Cancer Therapeutics and was subsequently recruited to OSI Pharmaceutical Inc. in 1992. At OSI, Dr. Haley served as Senior Director for Exploratory Cancer Research, Senior Research Director for Translational and EMT Research, and Senior Research Director for Discovery Research.
Dr. Haley holds numerous patents and has authored over 60 manuscripts related to the development of novel cancer therapeutics. He has presented numerous research seminars at national meetings, and he has served on a number of NCI grant review study sections. His strong academic background, as well as the depth of his experience in the Pharmaceutical industry, has uniquely qualified him to foster partnerships with peer institutions and with biotechnology and pharmaceutical companies, with the vision of developing novel approaches to cancer therapies at Stony Brook Medicine.
Kenneth R. Shroyer, MD, PhD
The Marvin Kuschner Professor and Chair of Pathology